Support & Resources

TRODELVY Logo

TRODELVY ACCESS SERVICES is a patient access and reimbursement support program. It will help you understand specific coverage and reimbursement guidelines for TRODELVY 180 mg single-dose vial.

Reimbursement support services include:

  • Benefits and coverage
  • Out-of-pocket cost assessment
  • Patient support programs
  • Alternate assistance options

Patient access support includes:

  • TRODELVY Savings Program for eligible patients with commercial or private insurance*
  • Immunomedics Patient Assistance Program (PAP) for qualified uninsured or underinsured patients to receive TRODELVY at no cost
  • Referrals to independent third-party assistance organizations

TRODELVY support may vary based on application criteria and is subject to change or discontinuation. Physician office must submit prior authorizations and appeals.

* Patients must not be enrolled in a government-sponsored program and must meet certain other eligibility criteria to qualify for this program. If approved, the patient may pay as little as $0, with a maximum benefit of $25,000 per year.

Immunomedics PAP provides TRODELVY free of charge for eligible patients who are uninsured or underinsured. To qualify for assistance, patients must meet certain eligibility criteria.

Patients with Medicare or other government insurance who need assistance with cost-share requirements for TRODELVY may be eligible for co-pay or co-insurance assistance through an independent co-pay assistance foundation. Case Managers can verify patient’s coverage for TRODELVY. If co-pay assistance needs are identified, the Case Manager can provide information about any available foundations. The foundation will determine the patient’s eligibility for co-pay or co-insurance assistance based on their own criteria and will contact the patient directly regarding the application process.

Use the Patient Enrollment Form to enroll in TRODELVY ACCESS SERVICES

For more information, please contact TRODELVY ACCESS SERVICES

TRODELVY SAVINGS PROGRAM

TRODELVY

The TRODELVY Savings Program provides savings on out-of-pocket expenses of TRODELVY 180 mg single-dose vial, up to $25,000 annually for commercially or privately insured patients. Terms and conditions apply.§

How It Works

Your doctor's office or TRODELVY ACCESS SERVICES can help you determine eligibility and apply. Download the Enrollment Form and then talk to your doctor about the enrollment process.

§ Terms & Conditions
Eligible patients receive up to a maximum benefit of $25,000 per year. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. No claims for reimbursement for TRODELVY units dispensed under the TRODELVY Co-pay/Co-insurance Savings Program may be submitted to any public payor (ie, Medicare, Medicaid, Medigap, Tricare, VA, and DoD). Product dispensed pursuant to program rules and federal and state laws. Immunomedics reserves the right to rescind, revoke, or amend this offer without notice at any time. Not valid if reproduced. This offer is valid in the United States. Void where prohibited by law.

Immunomedics Patient Assistance Program

The Immunomedics Patient Assistance Program (PAP) helps eligible patients who are uninsured or underinsured obtain access to TRODELVY at no cost.

Third-party Assistance Referrals

Case Managers are available to provide you with information about other organizations that may be able to help you with co-pays, deductibles, and insurance premiums related to your TRODELVY treatment.

Downloadable Resources

These materials were created to help inform you about mTNBC and TRODELVY.

Download the full Prescribing Information including the Patient Information

TNBC Community Support

There are additional resources that may be helpful to patients, families, and caregivers dealing with breast cancer. The following resources are not controlled or owned by Immunomedics, and Immunomedics is not responsible for their content.

Breastcancer.org: A complete resource for patients with breast cancer.

Living Beyond Breast Cancer®: Information, community, and support for people whose lives have been impacted by breast cancer.

Metavivor: Dedicated to increasing awareness of advanced breast cancer and equity in research and patient support.

Share Cancer Support: A supportive community of women affected by breast or ovarian cancer.

Sharsheret®: A Jewish breast cancer organization that helps women and their families face breast cancer.

Sisters Network® Inc: Committed to increasing local and national attention to the devastating impact that breast cancer has in the African American community.

Triple Negative Breast Cancer Foundation®: Dedicated to raising awareness of triple-negative breast cancer.

Young Survival Coalition®: Dedicated to the critical issues unique to young women who are diagnosed with breast cancer.

All referenced trademarks are the property of their respective owners.

INDICATION

TRODELVY is a prescription medicine used to treat adults with breast cancer that is estrogen and progesterone hormone receptor (HR) negative, and human epidermal growth factor receptor 2 (HER2)-negative (also called triple-negative breast cancer), and that has spread to other parts of the body (metastatic), and who previously received at least two therapies for metastatic disease.

TRODELVY is approved based on tumor response. Data are not yet available to show if TRODELVY improves survival or symptoms.

It is not known if TRODELVY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

TRODELVY can cause serious side effects, including:

  • Low white blood cell count (neutropenia). Low white blood cell counts are common with TRODELVY and can sometimes be severe and lead to infections that can be life-threatening. Your healthcare provider should check your blood cell counts during treatment with TRODELVY. If your white blood cell count is too low, your healthcare provider may need to lower your dose of TRODELVY, give you a medicine to help prevent low blood cell count with future doses of TRODELVY, or in some cases may stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection during treatment with TRODELVY: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
  • Severe diarrhea. Diarrhea is common with TRODELVY and can also be severe. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control your diarrhea. If you lose too much body fluids (dehydration), your healthcare provider may need to give you fluids and electrolytes to replace body salts. If diarrhea happens later in your treatment, your healthcare provider may check you to see if the diarrhea may be caused by an infection. Your healthcare provider may decrease your dose or stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
    • Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of losing too much body fluid (dehydration) and body salts, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.

Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:

  • have been told that you carry a gene for uridine diphosphate-glucuronosyl transferase A1 (UGT1A1)*28. People who carry this gene have an increased risk of getting side effects with TRODELVY, especially low white blood cell counts.
  • have liver problems.
  • are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY.
    • Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time.
    • Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.
    • Tell your healthcare provider right away if you or your partner become pregnant during treatment with TRODELVY.
  • are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.

TRODELVY can cause serious side effects, including:

  • See “TRODELVY can cause serious side effects” above for information about low white blood cell count and diarrhea.
  • Severe and life-threatening allergic reactions. TRODELVY can cause severe and life-threatening allergic reactions during infusion (infusion-related reactions). Tell your healthcare provider or nurse right away if you get any of the following symptoms of an allergic reaction during an infusion of TRODELVY or within 24 hours after you receive a dose of TRODELVY: swelling of your face, lips, tongue, or throat; hives; skin rash or flushing of your skin; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; chills or shaking chills (rigors); or fever.
  • Nausea and vomiting. Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting. You should be given medicines to take home with you, along with instructions about how to take them to help prevent and treat any nausea and vomiting after you receive TRODELVY. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.

The most common side effects of TRODELVY also include tiredness, decreased red blood cell count, hair loss, constipation, rash (See “Severe and life-threatening allergic reactions” above), decreased appetite and stomach-area (abdomen) pain.

TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.

These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.